Results 11 to 20 of about 6,463,095 (311)

Progression-free survival versus post-progression survival and overall survival in WHO grade 2 gliomas

Acta Oncologica
Background and purpose: Progression-free survival (PFS) remains to be validated as an outcome measure for diffuse WHO grade 2 gliomas, and knowledge about the relationships between PFS, post-progression survival (PPS), and overall survival (OS) in this ...
Lisa Millgård Sagberg, Øyvind Salvesen, Asgeir Store Jakola, Erik Thurin, Eddie de Dios, Noah L.A. Nawabi, John L. Kilgallon, Joshua D. Bernstock, Vasileios K. Kavouridis, Timothy R. Smith, Ole Solheim   +10 more
doaj   +4 more sources

Progression‐free survival in oncology: Caveat emptor! [PDF]

Basic & Clinical Pharmacology & Toxicology, 2018
AbstractOverall survival (OS) is the undisputed gold standard efficacy end‐point in cancer drug trials. It is with growing concern that we observe how progression‐free survival (PFS) gains ground as surrogate end‐point in its place. PFS has appeal because it is resource‐efficient, but it has severe shortcomings.
Bergmann, Troels K; id_orcid 0000-0001-8313-0721, Christensen, Mette Marie H, Henriksen, Daniel; id_orcid 0000-0003-1303-6195, Haastrup, Maija Bruun, Damkier, Per; id_orcid 0000-0003-0591-7187   +4 more
openaire   +2 more sources

An Audit Strategy for Progression-Free Survival [PDF]

Biometrics, 2011
In randomized clinical trials, the use of potentially subjective endpoints has led to frequent use of blinded independent central review (BICR) and event adjudication committees to reduce possible bias in treatment effect estimators based on local evaluations (LE). In oncology trials, progression-free survival (PFS) is one such endpoint.
Dodd, Lori E., Korn, Edward L., Freidlin, Boris, Gray, Robert, Bhattacharya, Suman   +4 more
openaire   +3 more sources

Clinicogenomic Insights for Progression-Free Survival in Prostate Cancer. [PDF]

Int J Environ Res Public Health
Prostate cancer (PrCa), the second most common cancer diagnosed in men globally, remains a critical challenge in precision oncology. While PrCa can be deadly, it is highly treatable if detected early. Identifying associative factors influencing disease progression risks can help inform preliminary steps that will further the expedition of clinical ...
Ofori-Minta K, Wang B, Mohl JE, Mandal A, Leung MY.   +4 more
europepmc   +3 more sources

Progression-free survival and overall survival of the cohort.

, 2022
Progression-free survival and overall survival of the cohort.
Chun-Fu Lin (12174572), Yee Chao (804364), Muh-Lii Liang (11204487), Keng-Li Lan (1459669), Tai-Tong Wong (48446), Feng-Chi Chang (435054), Yu-Mei Kang (12174569), Yi-Yen Lee (271429), Shih-Chieh Lin (63678), Hsin-Hung Chen (789932), Sanford P. C. Hsu (3177300), Yi-Wei Chen (48440)   +11 more
core   +1 more source

Progression-free survival analysis based on whether a complete response was attained.

, 2021
Progression-free survival analysis based on whether a complete response was attained.
Elvina Almuradova (11663234), Merve Guner Oytun (11663231), Mustafa Harman (11663237), Ruchan Uslu (816262), Gulcan Bulut (11663228), Bulent Karabulut (11663240)   +5 more
core   +2 more sources

Progression-free survival according to MTV.

, 2022
Progression-free survival according to MTV.
Nina Jehanno (11949663), Pierre Payoux (3484706), Daniel Orbach (11949669), Marie-Pierre Castex (11949666), Thomas Mognetti (582844), Corradini Nadège (11949672), Helio Fayolle (11949660), Anne Hitzel (11949675), Valerie Lauwers-Cances (437048)   +8 more
core   +1 more source

Population Pharmacokinetics of Palbociclib and Its Correlation with Clinical Efficacy and Safety in Patients with Advanced Breast Cancer

Pharmaceutics, 2022
Neutropenia is the most frequent dose-limiting toxicity reported in patients with metastatic breast cancer receiving palbociclib. The objective of this study was to investigate the pharmacokinetic–pharmacodynamic (PK/PD) relationships for toxicity (i.e.,
Perrine Courlet, Evelina Cardoso, Carole Bandiera, Athina Stravodimou, Jean-Philippe Zurcher, Haithem Chtioui, Isabella Locatelli, Laurent Arthur Decosterd, Léa Darnaud, Benoit Blanchet, Jérôme Alexandre, Anna Dorothea Wagner, Khalil Zaman, Marie Paule Schneider, Monia Guidi, Chantal Csajka   +15 more
doaj   +1 more source

A nomogram to predict the progression-free survival of clival chordoma [PDF]

Journal of Neurosurgery, 2021
OBJECTIVE Chordoma shows poor patient prognosis because of its high recurrence rate. Even though many clinical factors and biomarkers are reported to be associated with prognosis, no prediction model has been applied clinically.
Yixuan, Zhai, Jiwei, Bai, Mingxuan, Li, Shuai, Wang, Chuzhong, Li, Xinting, Wei, Yazhuo, Zhang   +6 more
openaire   +2 more sources

Clinical Characteristics, Course, and Long-Term Outcomes in Patients with Talaromyces marneffei Infection: A 10-Year Retrospective Cohort Study

Infectious Diseases and Therapy, 2023
Introduction Talaromyces marneffei (T. marneffei), a dimorphic fungus, causes local or disseminated infection in humans. We aimed to analyze the clinical characteristics, prognostic factors, and survival outcomes of patients with T.
QingLiang Yu, Meifang Wei, Rong Xiao, Xiaona Liang, Siqiao Liang, Nan Ma, Siyao Wu, Yan Ning, Jingmin Deng, Meiling Yang, Quanfang Chen, Wen Zeng, Meihua Li, Xiaokai Feng, Zhiyi He   +14 more
doaj   +1 more source